(Total Views: 249)
Posted On: 07/01/2025 6:35:46 PM
Post# of 154896
Sorry meant to include a reference from DocJ…
“In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting.”
Expect the same in 22-ish solid tumors.
“In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting.”
Expect the same in 22-ish solid tumors.
(0)
(0)
